Pear Therapeutics, Inc. announced resignation of Corey McCann, M.D., Ph.D. as President. Christopher D.T. Guiffre, J.D., M.B.A., the Company's Chief Operating Officer, and Chief Financial Officer will serve as the Company's principal executive officer following the departure of Dr. McCann. Dr. McCann will continue to serve as a member of the Board.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.000001 USD | -99.00% | -.--% | -.--% |
Mar. 22 | Disclosure Statement and Plan Approved on Interim Basis for Pear Therapeutics, Inc. | CI |
Mar. 04 | Combined Liquidation Plan and Disclosure Statement Filed by Pear Therapeutics, Inc. | CI |
1st Jan change | Capi. | |
---|---|---|
-.--% | 142 | |
+1.51% | 42.75B | |
+8.57% | 41.34B | |
+49.22% | 41.61B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- PEARQ Stock
- News Pear Therapeutics, Inc.
- Pear Therapeutics, Inc. Announces Executive Changes